On May 11, 2020, Recro Pharma issued a press release reporting its first quarter 2020 financial results for the three months ended March 31, 2020. In connection with reporting worse than expected financial results for the first quarter, the Company revised its 2020 revenue guidance downward from a range of $97-$100 million to a range of $80-$85 million. In revising its guidance downward, the Company cited a number of factors, including (1) increased competition, (2) slower than expected new business growth primarily attributable to COVID-19, and (3) notifications by two customers of discontinuations for two commercial product lines.

Following this news, shares of Recro Pharma common stock plummeted by over 41% in midday trading.

If you purchased Recro Pharma common stock or other Recro Pharma securities and would like to discuss our investigation, please contact us by emailing
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
or by calling (646) 315-9003.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Kaplan Fox & Kilsheimer LLP, with offices in New York, San Francisco, Los Angeles, Chicago and New Jersey, has many years of experience in prosecuting investor class actions. For more information about Kaplan Fox & Kilsheimer LLP, you may visit our website at www.kaplanfox.com. If you have any questions about this investigation, your rights, or your interests, please contact:

Frederic S. FoxKAPLAN FOX & KILSHEIMER LLP850 Third Avenue, 14th FloorNew York, New York 10022(646) 315-9003E-mail:
This e-mail address is being protected from spambots. You need JavaScript enabled to view it